Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018–2020

References

• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–6. PMID: 21993636; PMCID: PMC4349422. doi:10.1007/978-1-61779-346-2_1.
   PubMedGoogle Scholar
• Branham S. Serological relationships among meningococci. Bact Rev. 1953;17(3):175–88. doi:10.1128/br.17.3.175-188.1953.
   PubMedGoogle Scholar
• European Center for Disease Control. Invasive meningococcal disease. Annual Epidemiological Report for 2017. [accessed 2021 Sept 25, at 18:13]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-meningococcal-disease.pdf.
   Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126(5):514–22. doi:10.1093/infdis/126.5.514.
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Bottomley MJ, Dʻ-Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J Exp Med. 2016;213(4):469–81. doi:10.1084/jem.20151960. Epub 2016 Mar 28. PMID: 27022144; PMCID: PMC4821650.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Banzhoff A, Azzari C, De Wals P, Marlow R, Marshall H, Pizza M, Rappuoli R, Bekkat-Berkani R. Recent advances in meningococcal B disease prevention: real-world evidence from 4cmenb vaccination. J Infect. 2021;83(1):17–26. doi:10.1016/j.jinf.2021.04.031. Epub 2021 Apr 30. PMID: 33933528.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Trumenba. [accessed 2021 Sept 25, at 18:22]. https://www.fda.gov/vaccines-blood-biologics/vaccines/trumenba.
   Google Scholar
• European medicines agency. Trumenba. Summary of product characteristics. 2020 [accessed 2021 Sept 25, at 18:27]. https://www.ema.europa.eu/en/medicines/human/EPAR/trumenba.
   Google Scholar
• Italian Drug Authority (Agenzia Italiana del Farmaco). Classificazione, ai sensi dellʻart. 12, Comma 5, Legge 8 Novembre 2012, N. 189, del medicinale per uso umano «trumenba», approvato con procedura centralizzata. (Determina N. 1366/2017). Gazzetta Ufficiale della Repubblica Italiana. 2017;190:150.
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–100. doi:10.1128/IAI.72.4.2088-2100.2004. Erratum in: Infect Immun. 2017 May 23;85(6): PMID: 15039331; PMCID: PMC375149.
   PubMed Web of Science ®Google Scholar
• Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379–89. doi:10.1086/600141. PMID: 19534597.
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086–93. doi:10.1016/j.vaccine.2010.06.083. Epub 2010 Jul 7. PMID: 20619376.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, et al. B1971009 and B1971016 trial investigators. A Bivalent Meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349–62. doi:10.1056/NEJMoa1614474. PMID: 29236639.
   PubMed Web of Science ®Google Scholar
• Beeslaar J, Absalon J, Anderson AS, Eiden JJ, Balmer P, Harris SL, Jones TR, Oʻ-Neill RE, Pregaldien JL, Radley D et al. MenB-Fhbp vaccine protects against diverse Meningococcal Strains in adolescents and young adults: post Hoc analysis of two phase 3 studies. Infect Dis Ther. 2020;9(3):641–56. doi:10.1007/s40121-020-00319-0. Epub 2020 Jul 22. PMID: 32700260; PMCID: PMC7452968.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification, 2nd ed., 2019 [accessed 2021 Sept 25, at 19,04]. https://www.who.int/publications/i/item/causality-assessment-aefi-user-manual-2019.
   Google Scholar
• Stefanizzi P, De Nitto S, Spinelli G, Lattanzio S, Stella P, Ancona D, Dellʻ-Aera M, Padovano M, Soldano S, Tafuri S, et al. Post-Marketing active surveillance of adverse reactions following influenza cell-based quadrivalent vaccine: an Italian prospective observational study. Vaccines (Basel). 2021;9(5):456. doi:10.3390/vaccines9050456. PMID: 34064483; PMCID: PMC8147936.
   PubMed Web of Science ®Google Scholar
• Tafuri S, Fortunato F, Gallone MS, Stefanizzi P, Calabrese G, Boccalini S, Martinelli D, Prato R. Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine. 2018 ;36(8):1072–77. doi:10.1016/j.vaccine.2018.01.018. Epub 2018 Jan 19. PMID: 29358055.
   PubMed Web of Science ®Google Scholar
• Tafuri S, Gallone MS, Calabrese G, Germinario C. Adverse events following immunization: is this time for the use of WHO causality assessment? Expert Rev Vaccines. 2015;14(5):625–27. doi:10.1586/14760584.2015.1029460. Epub 2015 Mar 25. PMID: 25805053.
   PubMed Web of Science ®Google Scholar
• Bonanni P, Villani A, Scotti S, Biasci P, Russo R, Maio T, Vitali Rosati G, Moscadelli A, Conforti G, Azzari C, et al. The recommended lifetime immunization schedule from the board of vaccination calendar for life in Italy: A continuing example of impact on public health policies. Vaccine. 2021;39(8):1183–86. doi:10.1016/j.vaccine.2021.01.019. PMID: 33589048.
   PubMed Web of Science ®Google Scholar
• Regione Puglia. DELIBERAZIONE DELLA GIUNTA REGIONALE 15 maggio 2018, n. 779 L.R. n.67 del 29.12.2017, art.60: «Modifica art. 52 della legge regionale 30 dicembre 2016, n. 40. Disposizioni in materia di vaccinazione ‘anti meningococcoʻ» e modifica DGR n. 113/2018. Approvazione del nuovo Calendario Vaccinale per la Vita 2018 della Regione Puglia. Bollettino Ufficiale della Regione Puglia - n. 77 del 11-6-2018.
   Google Scholar
• AIFA – gruppo di Lavoro sullʻanalisi dei segnali dei vaccini. Guida alla valutazione delle reazioni avverse osservabili dopo vaccinazione. 2016 [accessed 2021 Sept 25, at 07,46]. http://www.aifa.gov.it/sites/default/files/Guida_valutazione_reazioni_avverse_osservabili_dopo_vaccinazione_2.pdf.
   Google Scholar
• European Medical Agency. Important medical event terms list version (MedDRA) – version 24.0. [accessed 2021 Sept 25, at 07,53]. https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance/eudravigilance-system-overview.
   Google Scholar
• Stefanizzi P, Stella P, Ancona D, Malcangi KN, Bianchi FP, De Nitto S, Ferorelli D, Germinario CA, Tafuri S. Adverse events following Measles-Mumps-Rubella-Varicella vaccination and the case of Seizures: a post marketing active surveillance in Puglia Italian region, 2017-2018. Vaccines (Basel). 2019;7(4):140. doi:10.3390/vaccines7040140. PMID: 31591347; PMCID: PMC6963278.
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lucksinger GH, Absalon J, Beeslaar J, Eiden J, Jansen KU, York LJ, Quinn A, Graversen ME, Perez JL. A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults. Vaccine. 2016;34(12):1465–71. doi:10.1016/j.vaccine.2016.01.044. Epub 2016 Feb 1. PMID: 26845739.
   PubMed Web of Science ®Google Scholar
• Duffy J, Marquez P, Dores GM, Ng C, Su J, Cano M, Perez-Vilar S. Safety surveillance of Bivalent Meningococcal Group B vaccine, vaccine adverse event reporting system, 2014-2018. Open Forum Infect Dis. 2020;7(12):ofaa516. doi:10.1093/ofid/ofaa516. PMID: 33324721; PMCID: PMC7724509.
   PubMed Web of Science ®Google Scholar
• Stefanizzi P, De Nitto S, Patano F, Bianchi FP, Ferorelli D, Stella P, Ancona D, Bavaro V, Tafuri S. Post-Marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospective study in Apulia region (ITALY), 2009-2017. Hum Vaccin Immunother. 2020;16(8):1875–83. doi:10.1080/21645515.2019.1704124. Epub 2020 Feb 10. PMID: 32040350; PMCID: PMC7482746.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo A, Bianchi FP, Martinelli A, Lattanzio S, Carbonara A, Diella G, Tafuri S, Stefanizzi P. Safety profile of recommended vaccinations in adolescents: data from surveillance of adverse events following immunization in Puglia (Italy), 2016-2020. Vaccines (Basel). 2021;9(11):1302. doi:10.3390/vaccines9111302. PMID: 34835232; PMCID: PMC8625412.
   PubMed Web of Science ®Google Scholar
• Mebrat A, Dube L, Kebede A, Aweke Z. Determinants of incomplete childhood vaccination among children aged 12-23 months in Gambella region, Southwest Ethiopia: a case control study. Ethiop J Health Sci. 2021;31(1):63–72. doi:10.4314/ejhs.v31i1.8. PMID: 34158753; PMCID: PMC8188105.
   PubMed Web of Science ®Google Scholar
• Tafuri S, Gallone MS, Cappelli MG, Martinelli D, Prato R, Germinario C. Addressing the anti-vaccination movement and the role of HCWs. Vaccine. 2014;32(38):4860–65. doi:10.1016/j.vaccine.2013.11.006. Epub 2013 Nov 18. PMID: 24262311.
   PubMed Web of Science ®Google Scholar
• Faranda D, Alberti T, Arutkin M, Lembo V, Lucarini V. Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: the AstraZeneca case for France and Italy. Chaos. 2021;31(4):041105. doi:10.1063/5.0050887. PMID: 34251248.
   PubMed Web of Science ®Google Scholar